Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.

BMC cancer

Volumn 10, Issue , 2010, Pages 529-

  Li, Jin ^a   Zhao, Xinmin ^b   Chen, Lei ^b   Guo, Haiyi ^b   Lv, Fangfang ^b   Jia, K ^b   Yv, K ^b   Wang, Fengqing ^b   Li, Chuan ^b   Qian, Jun ^b   Zheng, Chunlei ^b   Zuo, Yunxia ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APATINIB; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 77957264446     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-529     Document Type: Article

References (0)